InfuSystem Holdings Crecimiento futuro

Future controles de criterios 3/6

Se prevé un crecimiento anual de los beneficios y los ingresos de InfuSystem Holdings de 87.8% y 8% por año respectivamente. Se prevé que el BPA crezca en un 86.7% al año. Se espera que la rentabilidad financiera sea de 12.7% en 3 años.

Información clave

87.8%

Tasa de crecimiento de los beneficios

86.7%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Healthcare	16.3%
Tasa de crecimiento de los ingresos	8.0%
Rentabilidad financiera futura	12.7%
Cobertura de analistas	Low
Última actualización	12 Apr 2024

Actualizaciones recientes sobre el crecimiento futuro

Recent updates

If You Like EPS Growth Then Check Out InfuSystem Holdings (NYSEMKT:INFU) Before It's Too Late

Feb 19

Will InfuSystem Holdings' (NYSEMKT:INFU) Growth In ROCE Persist?

Feb 06

InfuSystem Holdings (NYSEMKT:INFU) Seems To Use Debt Quite Sensibly

Jan 24

If You Had Bought InfuSystem Holdings (NYSEMKT:INFU) Shares Three Years Ago You'd Have Earned 625% Returns

Jan 11

At US$18.99, Is InfuSystem Holdings Inc. (NYSEMKT:INFU) Worth Looking At Closely?

Dec 28

Previsiones de crecimiento de beneficios e ingresos

NYSEAM:INFU - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
12/31/2025	148	9	9	27	1
12/31/2024	135	3	4	22	2
12/31/2023	126	1	0	11	N/A
9/30/2023	123	1	-2	11	N/A
6/30/2023	118	1	-5	10	N/A
3/31/2023	113	0	-3	13	N/A
12/31/2022	110	0	2	18	N/A
9/30/2022	108	0	-1	17	N/A
6/30/2022	107	-1	1	19	N/A
3/31/2022	104	0	2	20	N/A
12/31/2021	102	1	2	18	N/A
9/30/2021	100	12	8	22	N/A
6/30/2021	99	15	12	25	N/A
3/31/2021	100	18	8	22	N/A
12/31/2020	97	17	3	20	N/A
9/30/2020	94	7	-2	17	N/A
6/30/2020	90	6	-10	14	N/A
3/31/2020	84	2	-10	13	N/A
12/31/2019	81	1	-9	14	N/A
9/30/2019	77	0	-7	13	N/A
6/30/2019	72	-1	-3	11	N/A
3/31/2019	69	-2	1	12	N/A
12/31/2018	67	-1	3	11	N/A
9/30/2018	67	-19	7	12	N/A
6/30/2018	67	-18	8	11	N/A
3/31/2018	66	-19	7	10	N/A
12/31/2017	65	-21	5	8	N/A
9/30/2017	63	-3	N/A	8	N/A
6/30/2017	63	-3	N/A	7	N/A
3/31/2017	64	-2	N/A	6	N/A
12/31/2016	65	0	N/A	8	N/A
9/30/2016	67	2	N/A	5	N/A
6/30/2016	68	3	N/A	5	N/A
3/31/2016	66	3	N/A	9	N/A
12/31/2015	65	3	N/A	7	N/A
9/30/2015	63	2	N/A	8	N/A
6/30/2015	62	2	N/A	9	N/A
3/31/2015	61	2	N/A	6	N/A
12/31/2014	61	3	N/A	7	N/A
9/30/2014	61	3	N/A	7	N/A
6/30/2014	59	3	N/A	7	N/A
3/31/2014	58	2	N/A	5	N/A
12/31/2013	56	2	N/A	7	N/A
9/30/2013	54	1	N/A	4	N/A
6/30/2013	54	0	N/A	5	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: El pronóstico de crecimiento de los beneficios (87.8% al año) de INFU es superior a la tasa de ahorro (2.3%).

Beneficios vs. Mercado: Se prevé que los beneficios (87.8% al año) de INFU crezcan más rápidamente que el mercado US (14.6% al año).

Beneficios de alto crecimiento: Se espera que los beneficios de INFU crezcan significativamente en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (8% al año) de INFU crezcan más despacio que el mercado de US (8% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 8% al año) de INFU crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: Se prevé que la rentabilidad financiera de INFU sea baja dentro de 3 años (12.7%).

Descubre empresas en crecimiento

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

Price

Mkt cap

E.Growth

Analysts Target

InfuSystem Holdings Crecimiento futuro

Future controles de criterios 3/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

InfuSystem Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023

Consensus EPS estimates fall by 25%, revenue upgraded

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2023

Consensus EPS estimates fall by 15%

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2022

Recent updates

InfuSystem Holdings, Inc., Annual General Meeting, May 16, 2024

InfuSystem Receives Notice from NYSE American Regarding Late Filing of Annual Report on Form 10-K

InfuSystem Holdings, Inc. announced delayed annual 10-K filing

Full year 2023 earnings: EPS in line with analyst expectations despite revenue beat

InfuSystem Holdings, Inc. Announces Resignation of R. Rimmy Malhotra as Member of the Board

InfuSystem Holdings, Inc. to Report Q4, 2023 Results on Mar 14, 2024

New minor risk - Shareholder dilution

InfuSystem Holdings, Inc. Provides Revenue Guidance for the Fourth Quarter of 2023

InfuSystem Holdings, Inc. to Report Q3, 2023 Results on Nov 07, 2023

CEO & Director exercised options and sold US$870k worth of stock

Consensus EPS estimates fall by 25%, revenue upgraded

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2023

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Now 20% undervalued

InfuSystem Holdings, Inc. to Report Q2, 2023 Results on Aug 03, 2023

President exercised options and sold US$79k worth of stock

Independent Director notifies of intention to sell stock

Now 20% undervalued after recent price drop

Now 21% undervalued after recent price drop

Consensus EPS estimates fall by 15%

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

InfuSystem Holdings, Inc. Reaffirms Earnings Guidance for the Full Year 2023

Executive VP & CFO exercised options and sold US$92k worth of stock

Full year 2022 earnings released: EPS: US$0.001 (vs US$0.069 in FY 2021)

Independent Director exercised options and sold US$101k worth of stock

Independent Director exercised options and sold US$114k worth of stock

Independent Director exercised options and sold US$114k worth of stock

Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

InfuSystem Holdings, Inc. Revises Earnings Guidance for the Year 2022

InfuSystem Holdings, Inc. to Report Q3, 2022 Results on Nov 08, 2022

InfuSystem Holdings, Inc. Announces the Appointment of R. Rimmy Malhotra to Board of Directors, Effective September 20, 2022

Independent Director exercised options and sold US$70k worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$56k worth of stock

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

InfuSystem Holdings Inc. Revises Earnings Guidance for the Year 2022

InfuSystem Holdings, Inc. to Report Q2, 2022 Results on Aug 04, 2022

InfuSystem Holdings, Inc.(NYSEAM:INFU) dropped from Russell 2000 Dynamic Index

Independent Director exercised options and sold US$206k worth of stock

Executive VP & Chief Commercial Officer exercised options and sold US$119k worth of stock

Independent Director exercised options and sold US$66k worth of stock

InfuSystem Holdings Inc. Approves Appointment of Ralph Boyd to the Company's Board

Consensus EPS estimates fall by 38%

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

InfuSystem Holdings Inc. Provides Earnings Guidance for the Year 2022

Price target decreased to US$21.67

InfuSystem Holdings Inc., Annual General Meeting, May 17, 2022

Director exercised options and sold US$175k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 49%

Independent Director recently bought US$107k worth of stock

Full year 2021 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorated over the past week

InfuSystem Holdings Inc. to Report Q4, 2021 Results on Feb 10, 2022

CEO & Director notifies of intention to sell stock

Insider exercised options and sold US$101k worth of stock

Third quarter 2021 earnings released: US$0.022 loss per share (vs US$0.15 profit in 3Q 2020)

Independent Director exercised options to buy US$399k worth of stock.

Investor sentiment improved over the past week

Consensus EPS estimates fall to US$0.19

Second quarter 2021 earnings released: EPS US$0.04 (vs US$0.21 in 2Q 2020)

InfuSystem Holdings Inc. Revises Earnings Guidance for the Full Year 2021

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

InfuSystem Holdings Inc. (NYSEAM:INFU) announces an Equity Buyback for $20 million worth of its shares.

Independent Chairman of the Board exercised options to buy US$421k worth of stock.

Infusystem Holdings Inc. Reaffirms Earnings Guidance for Full Year 2021

First quarter 2021 earnings released: EPS US$0.033 (vs US$0.021 loss in 1Q 2020)

CEO & Director exercised options and sold US$576k worth of stock